Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
Morning Overview on MSN
Gene editing advances raise real prospects for future DNA upgrades
The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, affecting over half a million people each year and causing about 300,000 ...
Researchers discovered the secret checkpoints that keep CRISPR precise, revealing how the tool shifts from inactive to active without misfiring. The insight could transform gene therapy, making ...
Nobel Prize winner and CRISPR DNA-editing pioneer Jennifer A. Doudna, PhD, spoke Thursday at Fred Hutch Cancer Center in Seattle. Her lecture kicked off the President’s Seminar series, presented by ...
This figure illustrates the evolution of CRISPR technology from 1987 to 2019, presented in a horizontal timeline format and categorized into four generations, each denoted by a distinct color: The ...
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results